{"transactions":[{"id":700524,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-07-30T20:31:32.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on July 28, 2027."}],"balance_after":31152,"source":{"system":"sec-edgar","filing":"0001437749-26-025076","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025076/rdgdoc.xml","form_type":"4"}},{"id":1015760,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-20T19:56:29.000Z","date":"2020-12-30","kind":"sale","planned":false,"acquired":false,"shares":209,"price":6.01,"value":1256.09,"ownership":{"direct":false,"nature":"Alpha Venture Capital Parner, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase and sale of AYTU common shares (the \"Shares\") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares.  The total sale price of 209 Shares on December 30, 2020, was $1,256.09.  THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000912282-25-001096","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225001096/form5.xml","form_type":"5"}},{"id":1015759,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-20T19:56:29.000Z","date":"2020-11-18","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.923,"value":9230.0,"ownership":{"direct":false,"nature":"Alpha Venture Capital Management, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase and sale of AYTU common shares (the \"Shares\") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares.  The total sale price of 209 Shares on December 30, 2020, was $1,256.09.  THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents total Shares held following stock splits on June 30, 2016 (12:1), August 25, 2017 (20:1), August 13, 2018 (20:1), December 10, 2020 (10:1) and January 6, 2023 (20:1)."}],"balance_after":50,"source":{"system":"sec-edgar","filing":"0000912282-25-001096","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225001096/form5.xml","form_type":"5"}},{"id":1021991,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-10-07T20:08:25.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest on October 3, 2026."}],"balance_after":20440,"source":{"system":"sec-edgar","filing":"0001437749-25-030634","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030634/rdgdoc.xml","form_type":"4"}},{"id":1371041,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-11-09T01:44:23.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting."}],"balance_after":10440,"source":{"system":"sec-edgar","filing":"0000912282-24-000764","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000764/form4.xml","form_type":"4"}},{"id":1807066,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-08-15T23:38:00.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which vest as follows:  1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023."}],"balance_after":8940,"source":{"system":"sec-edgar","filing":"0000912282-23-000300","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000300/form4.xml","form_type":"4"}},{"id":2076619,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:13:05.000Z","date":"2022-12-21","kind":"disposition_to_issuer","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021.  The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer."}],"balance_after":148805,"source":{"system":"sec-edgar","filing":"0001567619-22-021997","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922021997/doc1.xml","form_type":"4"}},{"id":2746697,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T21:26:30.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":187804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested:  1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer."}],"balance_after":188805,"source":{"system":"sec-edgar","filing":"0001567619-21-008238","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761921008238/doc1.xml","form_type":"4"}},{"id":3055549,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true}}],"security":"Employee Stock Option Grant","published_at":"2020-08-17T16:29:47.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates."}],"balance_after":40038,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001654954-20-009234","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000165495420009234/section16.xml","form_type":"4"}},{"id":3485442,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-06-20T01:00:01.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments, commencing on September 1, 2019."}],"balance_after":100000,"derivative":{"exercise_price":0.52,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-017507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017507/doc4.xml","form_type":"4"}},{"id":3490767,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":66667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490766,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":66667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":66667,"derivative":{"exercise_price":0.4,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490765,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"disposition_to_issuer","acquired":false,"shares":66667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490764,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2014-09-26","expiration_date":"2019-12-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490763,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":250000,"derivative":{"exercise_price":0.4,"exercise_date":"2014-09-26","expiration_date":"2019-12-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490762,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2014-09-26","expiration_date":"2019-12-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490761,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":33333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2017-07-28","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490760,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":33333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":33333,"derivative":{"exercise_price":0.4,"exercise_date":"2017-07-28","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490759,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"disposition_to_issuer","acquired":false,"shares":33333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2017-07-28","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490758,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2015-06-24","expiration_date":"2020-06-24","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490757,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":1000000,"derivative":{"exercise_price":0.4,"exercise_date":"2015-06-24","expiration_date":"2020-06-24","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490756,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.68,"exercise_date":"2015-06-24","expiration_date":"2020-06-24","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490755,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-05-08","kind":"exercise","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2015-02-16","expiration_date":"2020-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490754,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":75000,"derivative":{"exercise_price":0.4,"exercise_date":"2015-02-16","expiration_date":"2020-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490753,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2015-02-16","expiration_date":"2020-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490752,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":712499,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which AVCP participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by AVCP, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":9484825,"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490751,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":66667,"price":0.4,"value":26666.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":8772326,"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490750,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":250000,"price":0.4,"value":100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":8705659,"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490749,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":33333,"price":0.3,"value":9999.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":8455659,"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490748,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":1000000,"price":0.4,"value":400000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":8422326,"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3490747,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:14:47.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":75000,"price":0.4,"value":30000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\"). Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP, except to the extent of his pecuniary interest in such securities."}],"balance_after":7422326,"source":{"system":"sec-edgar","filing":"0000899243-19-017093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017093/doc4.xml","form_type":"4"}},{"id":3760331,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":250000,"derivative":{"exercise_price":0.5,"exercise_date":"2014-09-26","expiration_date":"2019-12-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760330,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":66667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":66667,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760329,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":33333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":33333,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760328,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":1000000,"derivative":{"exercise_price":0.675,"exercise_date":"2015-06-24","expiration_date":"2020-06-24","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760327,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":75000,"derivative":{"exercise_price":0.5,"exercise_date":"2015-02-06","expiration_date":"2020-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760326,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":250000,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760325,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760324,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":136563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":136563,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":136563},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760323,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2017."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760322,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760321,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760320,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":33973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":33973,"derivative":{"exercise_price":0.81,"exercise_date":"2015-06-01","expiration_date":"2024-10-06","underlying":"Common Stock","underlying_shares":33973},"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3760319,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:01:08.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":7578095,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":7578095,"source":{"system":"sec-edgar","filing":"0000899243-18-029255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029255/doc4.xml","form_type":"4"}},{"id":3762680,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2014-09-26","expiration_date":"2019-12-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762679,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":66667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762678,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":33333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762677,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.675,"exercise_date":"2015-06-24","expiration_date":"2020-06-24","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762676,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2015-02-06","expiration_date":"2020-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762675,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762674,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762673,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":136563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":136563},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762672,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in four equal quarterly installments commencing on September 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762671,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762670,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762669,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":33973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.81,"exercise_date":"2015-06-01","expiration_date":"2024-10-06","underlying":"Common Stock","underlying_shares":33973},"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3762668,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:29:31.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":7578095,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Alpha Venture Capital Partners, L.P. (\"AVCP\") and Alpha Venture Capital Fund, L.P. (\"ACVF\"), with 7,347,326 shares held by AVCP and 230,769 shares held by AVCF.  Carl Dockery is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP and AVCF, and is the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP and AVCF. Mr. Dockery disclaims beneficial ownership of the securities held by AVCP and AVCF, except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029188/doc4.xml","form_type":"4"}},{"id":3769071,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-13T21:30:28.000Z","date":"2018-11-08","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":250000,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-028717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318028717/doc4.xml","form_type":"4"}},{"id":3781123,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-29T17:27:08.000Z","date":"2018-10-24","kind":"grant","acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These are restricted shares which vest on October 24, 2028, subject to earlier vesting in certain situations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Aggregate amount indicated reflects 20-for-1 reverse split and includes additional 2,663 post-split restricted shares previously issued."}],"balance_after":152663,"source":{"system":"sec-edgar","filing":"0001213900-18-014580","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000121390018014580/ownership.xml","form_type":"4"}},{"id":3822888,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-09-07T22:24:24.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":33333,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the \"old\" warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the sole member of Alpha Advisors, LLC, the investment advisor for Alpha Venture Capital Partners, LP (\"AVCP\"), and the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest in such securities."}],"balance_after":33333,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-18-024031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318024031/doc4.xml","form_type":"4"}},{"id":3822887,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-09-07T22:24:24.000Z","date":"2018-01-31","kind":"disposition_to_issuer","acquired":false,"shares":33333,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the \"old\" warrant and the acquisition of a new one."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the sole member of Alpha Advisors, LLC, the investment advisor for Alpha Venture Capital Partners, LP (\"AVCP\"), and the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2017-07-28","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-18-024031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318024031/doc4.xml","form_type":"4"}},{"id":3897809,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-06-12T21:54:16.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-016227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318016227/doc4.xml","form_type":"4"}},{"id":4069682,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-10T01:07:20.000Z","date":"2018-02-07","kind":"grant","acquired":true,"shares":136563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model."}],"balance_after":136563,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":136563},"source":{"system":"sec-edgar","filing":"0000899243-18-003463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318003463/doc4.xml","form_type":"4"}},{"id":4080908,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-02-03T01:19:30.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":66667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the sole member of Alpha Advisors, LLC, the investment advisor for Alpha Venture Capital Partners, LP, and the managing member of Alpha Venture Capital Management, LLC, the general partner of Alpha Venture Capital Partners, LP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest in such securities."}],"balance_after":66667,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-18-002769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318002769/doc4.xml","form_type":"4"}},{"id":4080907,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-03T01:19:30.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":103586,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the sole member of Alpha Advisors, LLC, the investment advisor for Alpha Venture Capital Partners, LP, and the managing member of Alpha Venture Capital Management, LLC, the general partner of Alpha Venture Capital Partners, LP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest in such securities."}],"balance_after":7578095,"source":{"system":"sec-edgar","filing":"0000899243-18-002769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318002769/doc4.xml","form_type":"4"}},{"id":4167256,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-10T00:01:46.000Z","date":"2017-11-07","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of these shares, 3,250 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents (i) 53,250 restricted shares directly owned by the Reporting Person; and (ii) 41,865 shares indirectly owned by Alpha Venture Capital Partners, L.P."}],"balance_after":95115,"source":{"system":"sec-edgar","filing":"0001213900-17-011709","document":"f4110717dockery_aytubio.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000121390017011709/f4110717dockery_aytubio.xml","form_type":"4"}},{"id":4249099,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2017-07-31T21:40:22.000Z","date":"2017-07-28","kind":"grant","acquired":true,"shares":33333,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, Alpha Venture Capital Partners, LP (\"AVCP\") purchased from the issuer for a combined price of $50,000 (i) a $50,000 convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note, at an exercise price of $1.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest in such securities."}],"balance_after":33333,"derivative":{"exercise_price":1,"exercise_date":"2017-07-28","expiration_date":"2022-07-28","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0000899243-17-019349","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317019349/doc4.xml","form_type":"4"}},{"id":4249098,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-07-31T21:40:22.000Z","date":"2017-07-28","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, Alpha Venture Capital Partners, LP (\"AVCP\") purchased from the issuer for a combined price of $50,000 (i) a $50,000 convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note, at an exercise price of $1.00 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Does not include additional shares issuable upon conversion of accrued interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is the sole member of Alpha Advisors, LLC, the investment advisor for AVCP, and the managing member of Alpha Venture Capital Management, LLC, the general partner of AVCP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest in such securities."}],"balance_after":50000,"derivative":{"exercise_price":0.75,"exercise_date":"2017-07-28","expiration_date":"2018-01-31","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-17-019349","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317019349/doc4.xml","form_type":"4"}},{"id":4294825,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-06-05T21:14:34.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-17-015359","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015359/doc4.xml","form_type":"4"}},{"id":4379280,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant","published_at":"2017-03-17T20:24:06.000Z","date":"2017-03-16","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% vests on September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 2017, subject to the Grantee's continued service as an employee on such dates."}],"balance_after":6667,"derivative":{"exercise_price":0.82,"expiration_date":"2026-04-10","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001638599-17-000295","document":"doc4_4624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000163859917000295/doc4_4624.xml","form_type":"4"}},{"id":4379279,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant","published_at":"2017-03-17T20:24:06.000Z","date":"2017-03-16","kind":"grant","acquired":true,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."}],"balance_after":8334,"derivative":{"exercise_price":0.82,"exercise_date":"2016-04-11","expiration_date":"2026-04-10","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001638599-17-000295","document":"doc4_4624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000163859917000295/doc4_4624.xml","form_type":"4"}},{"id":4379278,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant","published_at":"2017-03-17T20:24:06.000Z","date":"2017-03-16","kind":"disposition_to_issuer","acquired":false,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% vests on September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 2017, subject to the Grantee's continued service as an employee on such dates."}],"balance_after":0,"derivative":{"exercise_price":3.23,"expiration_date":"2026-04-10","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001638599-17-000295","document":"doc4_4624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000163859917000295/doc4_4624.xml","form_type":"4"}},{"id":4379277,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant","published_at":"2017-03-17T20:24:06.000Z","date":"2017-03-16","kind":"disposition_to_issuer","acquired":false,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These options are 100% vested."}],"balance_after":0,"derivative":{"exercise_price":3.23,"exercise_date":"2016-04-11","expiration_date":"2026-04-10","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001638599-17-000295","document":"doc4_4624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000163859917000295/doc4_4624.xml","form_type":"4"}},{"id":4413324,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-02T00:03:21.000Z","date":"2017-02-27","kind":"exercise","acquired":false,"shares":416667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Alpha Venture Capital Partners, L.P."},"balance_after":0,"derivative":{"exercise_price":6,"exercise_date":"2016-05-06","expiration_date":"2021-05-06","underlying":"Common Stock","underlying_shares":416667},"source":{"system":"sec-edgar","filing":"0001638599-17-000233","document":"doc4_4574.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000163859917000233/doc4_4574.xml","form_type":"4"}},{"id":4413323,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27709,"kind":"person","name":"DOCKERY CARL","position":1,"cik":"0001618149","reported_name":"DOCKERY CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T00:03:21.000Z","date":"2017-02-27","kind":"exercise","acquired":true,"shares":416667,"price":0.75,"value":312500.25,"ownership":{"direct":false,"nature":"Alpha Venture Capital Partners, L.P."},"balance_after":837300,"source":{"system":"sec-edgar","filing":"0001638599-17-000233","document":"doc4_4574.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000163859917000233/doc4_4574.xml","form_type":"4"}}]}